Venus Remedies Secures Game-Changing Antibiotic Rights: MET-X to Combat Superbugs

Venus Remedies has struck a major deal with Infex Therapeutics, securing exclusive in-licensing rights to develop and commercialize MET-X in India. This breakthrough antibiotic targets drug-resistant Gram-negative Enterobacterales, addressing a critical WHO priority. MET-X, with its FDA QIDP designation, promises accelerated development and extended market exclusivity. This strategic move aligns with Venus Remedies' focus on combating antimicrobial resistance and expanding its innovative product portfolio. The partnership could significantly boost Venus Remedies' market position in the fight against superbugs, potentially driving future growth and addressing a pressing global health concern.

 

Sources: NSE, BSE, Infex Therapeutics